关注
Kåre I. Birkeland
Kåre I. Birkeland
在 medisin.uio.no 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a …
JA Dormandy, B Charbonnel, DJA Eckland, E Erdmann, ...
The Lancet 366 (9493), 1279-1289, 2005
52482005
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and …
F Cosentino, PJ Grant, V Aboyans, CJ Bailey, A Ceriello, V Delgado, ...
European heart journal 41 (2), 255-323, 2020
46002020
Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity
K Malmberg, L Rydén, H Wedel, K Birkeland, A Bootsma, K Dickstein, ...
European heart journal 26 (7), 650-661, 2005
14942005
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
AF Hernandez, JB Green, S Janmohamed, RB D'Agostino, CB Granger, ...
The Lancet 392 (10157), 1519-1529, 2018
13802018
The effects of acute and chronic exercise on PGC‐1α, irisin and browning of subcutaneous adipose tissue in humans
F Norheim, TM Langleite, M Hjorth, T Holen, A Kielland, HK Stadheim, ...
The FEBS journal 281 (3), 739-749, 2014
8882014
Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative …
M Kosiborod, MA Cavender, AZ Fu, JP Wilding, K Khunti, RW Holl, ...
Circulation 136 (3), 249-259, 2017
7362017
Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2
JW Haukeland, JK Damås, Z Konopski, EM Løberg, T Haaland, I Goverud, ...
Journal of hepatology 44 (6), 1167-1174, 2006
7082006
Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study
M Kosiborod, CSP Lam, S Kohsaka, DJ Kim, A Karasik, J Shaw, N Tangri, ...
Journal of the American College of Cardiology 71 (23), 2628-2639, 2018
4682018
Vitamin status in morbidly obese patients: a cross-sectional study
ET Aasheim, D Hofsø, J Hjelmesæth, KI Birkeland, T Bøhmer
The American journal of clinical nutrition 87 (2), 362-369, 2008
4542008
Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial
JW Haukeland, Z Konopski, HB Eggesbø, HL von Volkmann, ...
Scandinavian journal of gastroenterology 44 (7), 853-860, 2009
4372009
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs …
KI Birkeland, ME Jørgensen, B Carstensen, F Persson, HL Gulseth, ...
The lancet Diabetes & endocrinology 5 (9), 709-717, 2017
3762017
Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease.
BK Kilhovd, TJ Berg, KI Birkeland, P Thorsby, KF Hanssen
Diabetes care 22 (9), 1543-1548, 1999
3751999
Impact of ethnicity on gestational diabetes identified with the WHO and the modified International Association of Diabetes and Pregnancy Study Groups criteria: a population …
AK Jenum, K Mørkrid, L Sletner, S Vange, JL Torper, B Nakstad, ...
European journal of endocrinology 166 (2), 317-324, 2012
3402012
The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26 …
L Meneghini, SL Atkin, SCL Gough, I Raz, L Blonde, M Shestakova, ...
Diabetes care 36 (4), 858-864, 2013
3362013
A comparison of the health-related quality of life in patients with diabetic foot ulcers, with a diabetes group and a nondiabetes group from the general population
L Ribu, BR Hanestad, T Moum, K Birkeland, T Rustoen
Quality of life research 16, 179-189, 2007
2922007
Lifestyle changes may reverse development of the insulin resistance syndrome. The Oslo Diet and Exercise Study: a randomized trial
PA Torjesen, KI Birkeland, SA Anderssen, I Hjermann, I Holme, P Urdal
Diabetes care 20 (1), 26-31, 1997
2871997
Effect of rhEPO administration on serum levels of sTfR and cycling performance
KI Birkeland, J Stray-Gundersen, P Hemmersbach, J Hallen, E Haug, ...
Medicine and science in sports and exercise 32 (7), 1238-1243, 2000
2642000
The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study
AB Birkenaes, S Opjordsmoen, C Brunborg, JA Engh, H Jonsdottir, ...
Journal of Clinical Psychiatry 68 (6), 917-923, 2007
2392007
Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome
P Andersen, I Seljeflot, M Abdelnoor, H Arnesen, PO Dale, A Løvik, ...
Metabolism 44 (5), 611-616, 1995
2261995
Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine
KI Birkeland, PD Home, U Wendisch, RE Ratner, T Johansen, LA Endahl, ...
Diabetes care 34 (3), 661-665, 2011
2232011
系统目前无法执行此操作,请稍后再试。
文章 1–20